Investor Relations

Current Press Releases

Arch Biopartners’ Lead Drug LSALT Peptide to Enter the Canadian Treatments for COVID-19 (CATCO) Trial

  • LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys which is common in moderate to severe cases of COVID-19, regardless of variant type.
  • LSALT is the first novel therapeutic to join the Canadian Treatments for COVID-19 trial, a multi-centre adaptive, randomized, open-label, controlled clinical trial involving sixty-five hospitals across Canada.
  • CATCO is being conducted in conjunction with the World Health Organization’s SOLIDARITY trial, in collaboration with countries around the world and with support from the CIHR-funded Canadian Network of COVID-19 Clinical Trials Networks.
  • LSALT will be evaluated in the Canadian trial on the basis of results of its Phase II trial demonstrating that the LSALT group had less ventilation days than the placebo group. The CATCO trial will include a 320 patient arm to confirm LSALT’s safety and efficacy as a treatment for acute lung inflammation for hospitalized COVID-19 patients.
  • Phase ...
    Full Release

Unaware of Any Undisclosed Material Change

TORONTO, Oct. 15, 2021 (GLOBE NEWSWIRE) -- At the request of the Investment Industry Regulatory Organization of Canada (IIROC), Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) wishes to confirm that the Company’s management is unaware of any undisclosed material change in the Company’s operations that would account for the recent increase in market activity.

About Arch Biopartners

Arch Biopartners Inc. is a clinical stage company focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact.  Arch is developing a pipeline of new drug candidates that inhibit inflammation in the lungs, liver and kidneys via the dipeptidase-1 (DPEP-1) pathway for multiple medical indications.

Continuing under development in the Arch portfolio are: AB569, a potential new treatment for antibiotic resistant bacterial infections in wounds and the lungs; and, ‘Borg’ peptide coatings that increase corrosion resistance and ...
Full Release

Arch Biopartners Provides Update on Phase II Trial for LSALT Peptide

| Source: Arch Biopartners


TORONTO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today provided an update that the analysis of the results of the Phase II trial of its lead drug LSALT peptide (Metablok) is ongoing and will be disclosed to the public following third-party, scientific peer review.

After the recruitment of the last patient into the trial in early May, the Company’s Phase II data team reconciled the patient data collected from the seven clinical sites that participated in the trial. The database containing the trial data was then locked at the end of June, which enabled the start of data analysis in late ...
Full Release

Contact Arch Biopartners
Stay connected!

Subscribe for email updates

Get email alerts when news is published
Please check the options for Investor News and Science Updates to receive additional information about events and publications

Please enable the javascript to submit this form

Press Release Archives